Imugene (ASX:IMU) secured an orphan drug designation from the US Food and Drug Administration for Vaxinia, a treatment candidate for bile tract cancer, according to a Wednesday filing with the Australian bourse.
The orphan drug designation will allow the drugmaker to receive tax credits, waiver of specific administration fees, and a seven-year market exclusivity for Vaxinia, the filing said.
Imugene's shares rose 4% in recent Tuesday trade.
Price (AUD): $0.05, Change: $+0.0020, Percent Change: +4.17%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。